Massachusetts General Hospital gynecologic cancer research program director Michael Birrer, MD, PhD, explains how ovarian tumor discoveries in the lab are already impacting patient care. Instead of classifying tumors by where they are found inside the body -- as breast, lung or ovarian cancer -- researchers and clinicians are increasingly identifying cancers by their genetic signatures. With new insight into the biology of tumors, physicians can target cancer at the molecular level using smart drugs designed to attack tumor weaknesses. This strategy has proven effective for treating patients with various cancers, including those with advanced lung cancer and melanoma. Now, Mass General Cancer Center physician-scientists are applying those same principles to gynecologic oncology, redefining the way they view ovarian cancer. To learn more about innovative ovarian cancer treatments at MGH visit: http://www.massgeneral.org/cancer/services/treatmentprograms.aspx?id=1442 To see a list of open clinical
In 2012, Dr. Mo Motamedi, an assistant professor at Harvard Medical School and an assistant geneticist at MGH Cancer Center, received a V Scholar grant. Dr. Leif Ellisen, associate professor at MGH and Harvard Medical School, was awarded a Translational grant from the V Foundation. Hear their stories in this new #PassTheV video!
At the Massachusetts General Hospital Cancer Center, we are pioneering efforts to match smart drugs to a cancer's specific genetic mutation — to slow the cancer's growth — and in some cases, reduce it significantly. We know that our patients are unique and so are their tumors. Now their treatment can be, too.
On September 13, Hope on Wheels visited the Massachusetts General Hospital Cancer Center to award them with a Hope Grant. Dr. Quynn and Dr. Weinstein welcomed guests and spoke about the center and program.
After the presentation, the dealers were given a tour of the facility. Ironically, during the tour a mother, who was there with her family and her young daughter with cancer, recognized Peter from a previous event in Pennsylvania. She was thrilled to know that Hyundai was supporting the program that she brings her daughter to.
Physicians at the Massachusetts GeneralHospital Cancer Center have become leaders in the development of personalized medicine for cancer patients. Specifically, years of collaborative research among clinicians, pathologists and molecular biologists have led to the development of better and faster methods to "genotype"
cancers and identify the genetic abnormalities that drive particular tumors. In turn, these methods are giving rise to new treatment paradigms focused on genetic mutations that may be shared by different tumors, irrespective
of their tissue of origin.
When diagnosed with pancreatic cancer, avid marathoner Rich Pildis began the race of his life. At the direction of friends and family, he sought care from Dr. Andrew Warshaw of Massachusetts General Hospital who performed a whipple procedure, helping Rich get back to running and beating cancer to the finish line.
Beatriz Riordan a nearly 20-year survivor of Pancreatic Cancer and one of the first patients to undergo whipple procedure at Massachusetts General Hospital, discusses her care under the skillful hands of Dr. Andrew Warshaw.
Pancreatic cancer patients at the Massachusetts General Hospital Cancer Center benefit from the innovative work of The Andrew L. Warshaw Institute for Pancreatic Cancer Research which includes a community of scientists, oncologists, surgeons, radiation oncologists and interventional endoscopists whose mission is to extend and improve the lives of patients with pancreatic cancer. More information visit: http://www.massgeneral.org/warshawinstitute/